V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.82 USD -3.75% Market Closed
Market Cap: 76.3m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

VistaGen Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

VistaGen Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Operating Income
-$38.2m
CAGR 3-Years
-19%
CAGR 5-Years
-7%
CAGR 10-Years
-23%
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%

See Also

What is VistaGen Therapeutics Inc's Operating Income?
Operating Income
-38.2m USD

Based on the financial report for Jun 30, 2024, VistaGen Therapeutics Inc's Operating Income amounts to -38.2m USD.

What is VistaGen Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-23%

Over the last year, the Operating Income growth was 18%. The average annual Operating Income growth rates for VistaGen Therapeutics Inc have been -19% over the past three years , -7% over the past five years , and -23% over the past ten years .

Back to Top